Women's Health Issues Explored At BIO CEO & Investor Conference

  • Contact: Charles Craig
  • Phone: 202-962-9200
  • Recommend
  • Tweet
  • Print
  • Email

WASHINGTON, D.C. (Feb. 8, 1999) Among the investor sessions featured at the Biotechnology Industry Organization's (BIO) annual CEO & Investor Conference in New York, Feb. 24-26, is a program on "Vaccines and Women's Health Issues."

The session will highlight the latest advances in drugs and vaccines for treatment of diseases that strike women the most, such as lupus and breast, ovarian and cervical cancers. Companies participating in the session are Biomira Inc., Corixa Corp., La Jolla Pharmaceuticals and StressGen Biotechnologies Corp.

BIO's CEO & Investor Conference is different from most biotech investment conferences. Company presentations are grouped by disease or technology approach and CEOs will participate in roundtable discussions on a variety of business issues.

Other investor sessions will focus on cancer as well as the most advanced treatments for rheumatoid arthritis, cardiovascular diseases, infectious diseases and central nervous system disorders.

The conference will be held at the New York Palace Hotel. News media should contact Charles Craig (202-962-9200) to register.

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.